exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087872 RNA Name: hsa-miR-196b-5p RNA Type: miRNA Chromosome: chr7 Starnd: - Coordinate: Start Site(bp): 27169528 End Site(bp): 27169549 External Links: hsa-miR-196b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACP1 chr2 264140 278283 + ARHGAP28 chr18 6729718 6915716 + ARL5A chr2 151788984 151828492 - BLOC1S6 chr15 45587214 45615945 + C15orf41 chr15 36579626 36810248 + C19orf53 chr19 13774456 13778773 + COL6A2 chr21 46098112 46132848 + CS chr12 56271699 56300391 - FAM222B chr17 28755978 28855232 - HOXA7 chr7 27153716 27157936 - IGDCC3 chr15 65327127 65378002 - IGF2BP1 chr17 48997385 49056145 + LDOC1 chrX 141111605 141177129 - LYSMD2 chr15 51723011 51751585 - PDE6D chr2 231732433 231786272 - PFKFB3 chr10 6144934 6254644 + TMEM161B chr5 88189633 88269476 - XPO4 chr13 20777329 20903048 - XPO6 chr16 28097979 28211920 - ZMYND11 chr10 134465 254637 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0000095 chr1 95609446 95616975 + hsa_circ_0001522 chr5 122881110 122893258 + hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005034.3 chr2 75697583 75697996 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - GAS5 chr1 173858559 173868882 - H19 chr11 1995176 2001470 - KCNQ1OT1 chr11 2608328 2699994 - NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.